Drug Discovery and Translational Therapeutics

Mycetoma is a neglected tropical disease that disproportionately affects impoverished communities in tropical and subtropical regions. Its management is challenging due to the minimal treatment success rates, prolonged therapy, and is often associated with significant toxicity due to long-term systemic use. Consequently, there is a desperate and critical need to find new molecular entities to address this profound unmet clinical need. This effort relies on the dual framework of Drug Discovery—the strategic process of identifying and optimising novel chemical or biological agents—and Translational Therapeutics—the essential science of bridging laboratory findings to practical clinical solutions.

Despite this overlooked pharmaceutical landscape, the Mycetoma Research Centre and its partners have been pivotal in developing and testing novel compounds, ensuring that research efforts are ethically and contextually grounded.

The MRC and partners have worked to design and synthesise 47 pharmacomodulated imidazo [1,2-b] pyridazine derivatives using a simple synthetic pathway with good yields and purity. For more information, you can read the following paper:

https://www.sciencedirect.com/science/article/pii/S0223523424006019